U.S. FDA approves Reata's rare genetic disorder drug

Reata Pharmaceuticals

28/02/2023 22:51

Feb 28 (Reuters) - The U.S. Food and Drug Administration
on Tuesday approved Reata Pharmaceuticals Inc's  RETA.O  drug
Skyclarys for the treatment of a rare genetic disorder that
causes progressive damage to the nervous system. 
    Reata estimates the disorder, called Friedreich's ataxia,
affects about 5,000 patients in the United States. 

 (Reporting by Raghav Mahobe, Mariam E Sunny and Pratik Jain in
Bengaluru; Editing by Krishna Chandra Eluri)
 ((Raghav.Mahobe@thomsonreuters.com;))